Mineralys Therapeutics, Inc. 4

Eric Warren, Chief Commercial Officer of Mineralys Therapeutics (MLYS), exercised 7,438 stock options and sold 7,438 common shares on 2026-07-21 under a Rule 10b5-1 plan.

On July 21, 2026, Eric Warren, Chief Commercial Officer of Mineralys Therapeutics, Inc., exercised a stock option for 7,438 shares of common stock at an exercise price of $13.24 per share and immediately sold the same 7,438 shares at a weighted-average price of $26.8735 per share under a Rule 10b5-1 trading plan, effectively converting option value into cash with no net change in his directly held share count from this specific grant. Following these transactions, he reported beneficial ownership of 245,438 shares of common stock, with the option exercise valued at approximately $98,485 based on the exercise price and the sale proceeds totaling approximately $199,970, implying an after-transaction holding value of roughly $6.6 million using the sale price as a proxy.

Filing Facts

CIK

1933414

Ticker

MLYS

Form

4

Source Type

fda

Accession

0001916048-26-000009

Alert Tier

5